Meeting
2021 Gastrointestinal Cancers Symposium
Impact of omitting fluorouracil from FOLFIRI plus bevacizumab as second-line chemotherapy for metastatic colorectal cancer patients.
Authors
Yuki Matsubara
Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
Yuki Matsubara , Toshiki Masuishi , Takatsugu Ogata , Taiko Nakazawa , Kyoko Kato , Kazuki Nozawa , Yukiya Narita , Kazunori Honda , Hideaki Bando , Shigenori Kadowaki , Masashi Ando , Masahiro Tajika , Kei Muro
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Colorectal Cancer
Track
Colorectal Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 39, 2021 (suppl 3; abstr 76)
DOI
10.1200/JCO.2021.39.3_suppl.76
Abstract #
76
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2019 Gastrointestinal Cancers Symposium
ABT-165 plus FOLFIRI versus bevacizumab plus FOLFIRI in patients with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine/oxaliplatin and bevacizumab.
First Author: Zev A. Wainberg
Poster
2018 ASCO Annual Meeting
ABT-165 plus FOLFIRI vs bevacizumab (bev) plus FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine/oxaliplatin and bev.
First Author: Zev A. Wainberg
Poster
2014 ASCO Annual Meeting
A randomized phase III trial of mFOLFOX6 plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment for metastatic colorectal cancer: West Japan Oncology Group study 4407G (WJOG4407G).
First Author: Kentaro Yamazaki
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Effectiveness of biologic agents among Hispanics in the US with metastatic colorectal cancer.
First Author: Riya Jayesh Patel